Search Results

Argentina Plans to Commission RA-10 Multipurpose Reactor in 2027

Argentina's National Atomic Energy Commission (CNEA) and the Nuclear Affairs Secretariat recently stated that the RA-10 multipurpose research reactor at the Ezeiza Atomic Centre is planned to begin commissioning before the end of this year, with the goal of achieving operation in 2027. (Image source: CNEA) According to the project site, RA-10 is currently in its final phase, with approximately 530 workers completing the remaining construction and system testing in preparation for subsequent reactor commissioning and operation. The project is currently about 96% complete overall. RA-10 is a 30 MW open-pool multipurpose research reactor that will provide products and services to the medical, scientific, technological, and industrial sectors once completed. Among these, molybdenum-99 will be one of its key products...

2026-09-08

Baiyunshan Xike Visits Jiujiang, Jiangxi to Explore Nuclear Medicine Industry Chain Cooperation

Recently, a delegation from Guangzhou Baiyunshan Xike Health Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited (GP Corp.), visited Jiujiang City, Jiangxi Province, conducting field inspections and discussion exchanges in Ruichang City, Jiujiang Economic Development Zone, and Pengze County, focusing on cooperation across the full nuclear medicine industry chain. Liu Hong, Director of the Scientific Research Project Management Department of GP Corp. and Chairman and General Manager of Baiyunshan Xike, led the core team in exchanges with Chen Shuilian, Member of the Party Leadership Group and Vice Mayor of Jiujiang Municipal People's Government, as well as responsible officials from Ruichang City, Pengze County, and Jiujiang Economic Development Zone, reaching multiple consensuses on subsequent cooperation. The inspection covered key facilities including the Ruichang Institute of Nuclear Physics Applications, the Biomedical (Nuclear) Industrial Park in Jiujiang Economic Development Zone, and the Jiangxi Tianhong Nuclear Technology project site in Pengze County. The delegation conducted in-depth visits to research laboratories, industrial parks, and projects under construction to understand local capabilities in nuclear technology research, isotope R&D infrastructure, project construction progress, as well as land and industrial supporting conditions.

2026-09-07

Bruce Power Aims to Generate Over CAD 13.3 Billion in Economic Impact in Canada Over Next 18 Months

Bruce Power recently stated that over the next 18 months, the company expects to generate more than CAD 13.3 billion in economic impact across Canada, with related investments primarily stemming from its nuclear plant operations and life extension programs, supporting businesses and jobs in Ontario and other regions of Canada. Bruce Power stated that since launching the "Canada First" program in 2025, the company has invested over CAD 6.6 billion in Canada between January 2025 and June 2026, and plans to invest an additional CAD 7.7 billion by the end of 2027. The company noted that its spending within Canada accounts for more than 95% of total expenditures. As a nuclear operator located in Bruce County, Ontario...

2026-08-28

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Leshan Accelerates Construction of Medical Isotope Production Base to Promote Domestic Substitution of "Anti-Cancer Nuclear Drugs"

On August 11, at the Leshan special press conference of "Myriad Scenes in Sichuan · Embarking on the '15th Five-Year Plan'", Leshan Mayor Zhao Yingchun stated that Leshan is accelerating the construction of the largest and most comprehensive medical isotope production base in China. Upon completion, the project will help break the foreign monopoly and import dependence on related products, promote the domestic substitution of anti-cancer nuclear drugs, and enable more patients to access domestically produced drugs with lower prices and better efficacy. Zhao Yingchun noted that during the "14th Five-Year Plan" period, Leshan has focused on building the "China Green Silicon Valley", a world-class tourist destination, and a major regional transportation and logistics hub in the province, continuously promoting high-quality development, with its economic output surpassing 250 billion yuan...

2026-08-12

South Korea advances plan to produce medical isotopes using nuclear power plants, with lutetium-177 targeted for commercial production in 2031

South Korea is advancing plans to industrialize the production of radioisotopes using nuclear power plants, with the medical isotope lutetium-177 (Lu-177) designated as the first commercial target product. Korea Hydro & Nuclear Power stated that it plans to prioritize the commercialization of Lu-177 production, with the potential to later expand the product range to include isotopes such as cobalt-60, tritium-3, and helium-3. Lu-177 is a therapeutic radioisotope widely used in the global radiopharmaceutical market, applicable in radiopharmaceuticals for diseases such as prostate cancer and neuroendocrine tumors. Previously, South Korea relied entirely on imports for its Lu-177 supply. Due to its half-life of approximately 6.6 days, the entire process from production and transportation to drug preparation and patient administration...

2026-08-06

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04

Ontario Invests Additional $4.6 Million in McMaster Nuclear Reactor to Expand Medical Isotope Production Capacity

The Government of Ontario, Canada, recently announced an additional investment of $4.6 million in the McMaster Nuclear Reactor to expand the production capacity of life-saving medical isotopes, supporting more cancer patients in accessing the critical radioisotopes needed for diagnosis and treatment. From left to right: Josip Zikic, Chief Nuclear Officer at McMaster University; Nolan Quinn, Minister of Colleges and Universities, Research Excellence and Security; Stephen Lecce, Minister of Energy and Mining; Susan Tighe, President and Vice-Chancellor of McMaster University; and Victor Fedeli, Minister of Economic Development, Job Creation and Trade. (Georgia Kirkos/McMaster University) This investment builds on a previous $18 million...

2026-07-30

Urenco Isotopes Collaborates on EMIS Test Facility to Strengthen Europe's Enriched Lanthanide Isotope Supply Chain

On July 28, 2026, Urenco Isotopes announced a collaboration with RI Research Instruments to advance the construction of a dedicated Electromagnetic Isotope Separation (EMIS) test facility, aiming to strengthen the future European supply chain for enriched lanthanide elements and meet the growing demand for high-purity stable isotopes in scientific research and potential medical isotope applications. Lanthanides are rare earth metals, and their isotopes may be used in the future for cancer diagnosis and treatment. Currently, reliable sources of high-purity lanthanide stable isotopes remain limited, with the supply chain concentrated among a few producers, and Europe's local supply capacity is relatively insufficient. Under the collaboration arrangement, RI Research Instruments...

2026-07-29

CNNC achieves end-to-end process integration for the production of the medical isotope Terbium-161.

Recently, the China Institute of Atomic Energy (CIAE) under the China National Nuclear Corporation (CNNC) successfully established the entire production process for the emerging medical isotope Terbium-161 (161Tb), producing a 100-millicurie, high-purity

2026-07-27